Humacyte Inc (NASDAQ: HUMA) on Friday, plunged -1.15% from the previous trading day, before settling in for the closing price of $2.62. Within the past 52 weeks, HUMA’s price has moved between $1.15 and $9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 80.49%. With a float of $125.75 million, this company’s outstanding shares have now reached $155.12 million.
Let’s determine the extent of company efficiency that accounts for 220 employees. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.94%, while institutional ownership is 39.88%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 80.49% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 3.28 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 772.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Looking closely at Humacyte Inc (NASDAQ: HUMA), its last 5-days average volume was 4.87 million, which is a jump from its year-to-date volume of 3.77 million. As of the previous 9 days, the stock’s Stochastic %D was 51.61%. Additionally, its Average True Range was 0.25.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 38.92%, which indicates a significant decrease from 63.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.65% in the past 14 days, which was lower than the 122.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.80, while its 200-day Moving Average is $3.97. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $2.82. Second resistance stands at $3.05. The third major resistance level sits at $3.17. If the price goes on to break the first support level at $2.47, it is likely to go to the next support level at $2.35. Now, if the price goes above the second support level, the third support stands at $2.12.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 401.76 million based on 155,119K outstanding shares. Right now, sales total 0 K and income totals -148,700 K. The company made 520 K in profit during its latest quarter, and 39,140 K in sales during its previous quarter.
